We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+8.93%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$115M
AUM Growth
+$18.9M
Cap. Flow
+$18M
Cap. Flow %
15.6%
Top 10 Hldgs %
77.08%
Holding
48
New
17
Increased
12
Reduced
3
Closed
13

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.8M
2
PFE icon
Pfizer
PFE
+$6.41M
3
AMGN icon
Amgen
AMGN
+$4.66M
4
NGNE icon
Neurogene
NGNE
+$3.96M
5
XLRN
Acceleron Pharma
XLRN
+$3.22M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$13.5M
2
AGN
Allergan plc
AGN
+$7.37M
3
BMY icon
Bristol-Myers Squibb
BMY
+$6.45M
4
SNY icon
Sanofi
SNY
+$4.7M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.65M

Sector Composition

Rank Sector Weight
1 Healthcare 89.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
1
Pfizer
PFE
$141B
$22.1M 19.1%
660,266
+200,722
+44% +$6.41M
GSK icon
2
GSK
GSK
$100B
$20.4M 17.64%
+376,000
New +$19.8M
SHPG
3
DELISTED
Shire pic
SHPG
$13.6M 11.8%
74,000
-2,200
-3% -$397K
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$6.12M 5.3%
151,500
+48,500
+47% +$1.84M
VTRS icon
5
Viatris
VTRS
$19.8B
$6.05M 5.24%
140,000
+4,000
+3% +$177K
LCI
6
DELISTED
Lannett Company, Inc.
LCI
$5.47M 4.74%
57,500
+20,000
+53% +$1.71M
AMGN icon
7
Amgen
AMGN
$197B
$4.57M 3.95%
+30,000
New +$4.66M
CYNA
8
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$4.09M 3.54%
244,310
+210,594
+625% +$2.83M
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$3.36M 2.91%
+99,000
New +$3.22M
NGNE icon
10
Neurogene
NGNE
$745M
$3.3M 2.86%
+24,915
New +$3.96M
ADMS
11
DELISTED
Adamas Pharmaceuticals
ADMS
$2.7M 2.34%
178,240
+61,240
+52% +$1.01M
KYNB
12
Kyntra Bio
KYNB
$28.5M
$2.53M 2.19%
+6,160
New +$2.82M
CNCE
13
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$2.06M 1.78%
183,000
– –
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
$1.94M 1.68%
110,280
+50,000
+83% +$809K
ARRY
15
DELISTED
Array Biopharma Inc
ARRY
$1.85M 1.61%
+521,000
New +$1.7M
INSM icon
16
Insmed
INSM
$23.2B
$1.66M 1.44%
168,700
+128,700
+322% +$1.5M
PDSB icon
17
PDS Biotechnology
PDSB
$40.1M
$1.37M 1.19%
+6,792
New +$1.2M
RXDX
18
DELISTED
Ignyta, Inc.
RXDX
$1.27M 1.1%
235,000
+85,000
+57% +$566K
NERV icon
19
Minerva Neurosciences
NERV
$204M
$1.09M 0.95%
13,375
+9,112
+214% +$579K
ADXS
20
DELISTED
Advaxis Inc
ADXS
$1.01M 0.88%
8,333
+1,666
+25% +$213K
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
$974K 0.84%
+39,000
New +$1.06M
TRVN
22
DELISTED
Trevena, Inc.
TRVN
$945K 0.82%
+240
New +$1.13M
TBRA
23
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$942K 0.82%
75,000
+30,000
+67% +$279K
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$922K 0.8%
+145,250
New +$964K
IMDZ
25
DELISTED
Immune Design Corp.
IMDZ
$695K 0.6%
85,138
– –
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Nexthera Capital held 48 positions worth $115M, up 20% from $96.5M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Nexthera Capital deployed $18M of net new capital in Q2 2016, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was GSK: 376,000 shares worth $20.4M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Immunogen Inc, an estimated $549K trimmed.

  • Nexthera Capital's largest Q2 2016 buy was GSK: 376,000 shares worth $20.4M.
  • Nexthera Capital added most to Pfizer in Q2 2016, an estimated $6.41M increase.
  • Nexthera Capital's biggest Q2 2016 reduction was Immunogen Inc, cutting an estimated $549K.
  • Nexthera Capital fully exited Celgene Corp in Q2 2016, selling an estimated $13.5M.
  • Nexthera Capital's ten largest holdings make up 77% of its $115M portfolio in Q2 2016.
  • Nexthera Capital opened 17 new positions and closed 13 in Q2 2016.
  • Nexthera Capital's portfolio value rose 20% quarter-over-quarter to $115M.

Based on Nexthera Capital's 13F filing for Q2 2016, filed 15 Aug 2016.